Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 7 June 2021 Vol. No. 10; Issue No. 478

1. Sulkshane P, Pawar SN, Waghole R, Pawar SS, Rajput P, Uthale A, Oak S, Kalkar P, Wani H, Patil R, Nair S, Rane P, Teni T (2021). Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers. British Journal of Cancer.

2. Ranganathan P, Sengar M, Chinnaswamy G, Agrawal G, Arumugham R, Bhatt R, Bilimagga R, Chakrabarti J, Chandrasekharan A, Chaturvedi HK, Choudhrie R, Dandekar M, Das A, Goel V, Harris C, Hegde SK, Hulikal N, Joseph D, Kantharia R, Khan A, Kharde R, Khattry N, Lone MM, Mahantshetty U, Malhotra H, Menon H, Mishra D, Nair RA, Pandya SJ, Patni N, Pautu J, Pavamani S, Pradhan S, Thammineedi SR, Selvaluxmy G, Sharan K, Sharma BK, Sharma J, Singh S, Srungavarapu GC, Subramaniam R, Toprani R, Raman RV, Badwe RA, Pramesh CS (2021); National Cancer Grid of India. Impact of COVID-19 on cancer care in India: a cohort study. Lancet Oncology.

3. Shinghal A, Paul S, Chopra S, Gurram L, Scaria L, Kohle S, Rane P, Dheera A, Puravath J, Jain J, Swamidas J, Ghosh J, Gupta S, Rath S, Ghosh Laskar S, Agarwal JP (2021). Impact of COVID -19 pandemic on Gynaecological cancer radiation during complete nationwide lockdown: Observations and Reflections from Tertiary care institute in India. Advances in Radiation Oncology.

4. Sharma S, Sharma U, Chaudhary A, Naithani M, Naithani P, Prashar S, Sharma B, Nagar PK, Bhukya P, Bhalerao U, Singh M, Srivastava M, Barman M, Attri S, Gairolla J (2021). SARS-CoV-2: Insights from the Immunopathogenesis and Current Clinical Diagnosis and Therapeutic Strategies. Journal of Immunological Sciences. 5(2): 1-15.

5. Dev ID, Puranik AD, Purandare NC, Gupta T, Sridhar E, Shetty P, Moiyadi A, Agrawal A, Shah S, Rangarajan V (2021). Prognostic significance of 18F-FDG PET/CT parameters in IDH-1 wild-type GBM and correlation with molecular markers. Nuclear Medicine Communications.

6. Ghantasala S, Pai MGJ, Biswas D, Gahoi N, Mukherjee S, Manubhai KP, Nissa MU, Srivastava A, Epari S, Shetty P, Moiyadi A, Srivastava S (2021). Multiple Reaction Monitoring-Based Targeted Assays for the Validation of Protein Biomarkers in Brain Tumors. Frontiers in Oncology

7. Yadav S, Bal M, Rane S, Mittal N, Janu A, Patil A(2021). Carcinoma Cuniculatum of the Oral Cavity: A Series of 6 Cases and Review of Literature. Head and Neck Pathology.

8. Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, Arandkar S, Rotkopf R, Kapsack A, Lambiase G, Pellegrino B, Ben-Isaac E, Golani O, Addadi Y, Hajaj E, Eilam R, Straussman R, Yarden Y, Lotem M, Oren M (2021). TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences. 118(23):e2025631118.

9. Bapat P, Bhat S, Chakraborty C, Chirmule N, Kadam R, Kashyap S, Masurkar S, Paul R, Rao D, Reddy R, Togar T (2021). Mentoring during the COVID-19 pandemic:A perspective from graduate students in biomedical science studies in India. Proceedings of the Indian National Science Academy.


1. Rajashree Chittaranjan Kadam( 2021) Elucidating the role of Clusterin in human oral cancers. (HBNI No. LIFE09201304006) (Guide: Dr. Tanuja Teni).

2. Dhanashree Mundhe (2021) Assessing the role of Activins/Inhibins in human oral cancers. (HBNI No. LIFE09201304008) (Guide: Dr. Tanuja Teni).

Site of the Week

Protein Family Models is a collection of models representing homologous proteins with a common function.

desktop Image
Interesting Reads

Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, Carr D, Blaeschke F, Marson A, Doudna JA. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 35(9):109207, 2021.

Legends of Science
Rudolf Ludwig Carl Virchow Kedareshwar Banerjee

Kedareshwar Banerjee obtained his DSc (1929) from University of Kolkata. His contribution was in theoretical and experimental investigations on stress optic effect in isotropic solids, x-ray diffraction by liquids, determination of atomic arrangement in the crystals of naphalene and anthracene. He also worked on structures of organic crystals, metals, fibres and glass by x-ray, magnetic optical methods. He created active schools of research in crystallography in all over Indian institutes. He was Director, IACS (1959). He was a Fellow, National Academy of Sciences, Indian Association for the Cultivation of Science.

Andreas Vesalius Iqbal Singh Bhatia

Iqbal Singh Bhatia obtained his PhD (1949) from John Hopkins University, USA. His specialization was Biochemistry. His contribution was his research on Fructosan Biosynthesis, cardiolipin metabolism, polyphenols of tea fermentation, rumen biochemistry, and lipid metabolism in mammary glands. Dr. Bhatia was a Fellow of Royal Society of Chemistry (London), Member of Sigma Xi (USA), Biochemical Society (London), Society of Biological Chemists, Nutrition Society of India.

Do You Know?

In 2015, Sequencing of 243 biopsies of sun-exposed but healthy skin from 4 individuals showed a high burden of somatic mutations, including those known to drive skin cancer.

back Image
Cancer News
For Hairy cell leukemia, drug combination on leads to long-lasting remissions

03 June 2021, National Cancer Institute

In a small study, the combination of two targeted therapies led to long-lasting remissions for the majority of patients with hairy cell leukemia that had come back after previous treatments...

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

04 June 2021, ScienceDaily

A new treatment has potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a PARP inhibitor has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy...

CAR T-cell therapy trials for cancer treatment begin in Mumbai

07 June 2021, Hindustan Times, Mumbai

The clinical trial of an indigenously developed CAR T-cell therapy for blood cancer treatment has begun at Mumbai’s Tata Memorial Centre, said researchers of the Indian Institute of Technology, Bombay (IIT-B), who have developed this gene therapy.

� 2021 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)